Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > BMS enters into a USD$ 2 Billion with startup company

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Aug 10, 2022 12:07pm

167 Views

Post# 34885090

RE:RE:RE:BMS enters into a USD$ 2 Billion with startup company

100% agreed. Let's get an NR followed by posts about Oncy being acquired or partnered. BP is throwing massive amounts of cash around, but none towards us...yet. Reading about start-ups and preclinical companies getting multi billions is getting unnerving. Coffey...Parsons...get the sale done!!

<< Previous

Bullboard Posts

Next >>

MDA doubles satellite capacity in Canada’s largest space program